Design of Measles Virus Based Vaccines for Cancer

Viral vector systems are widely used to develop novel genetic approaches against various human diseases. Oncolytic measles viruses have shown great potential as cancer therapeutics. Creative Biolabs is a world leader in the field of cancer vaccine development. With our extensive experience and advanced platform, we are therefore confident in offering the best development services for measles virus-based vaccines. We guarantee the finest results for our customers all over the world.

Measles Virus

Measles virus (MeV) is a single-stranded, negative-sense, enveloped (non-segmented) RNA virus belonging to the genus Morbillivirus within the family Paramyxoviridae. Although at least 20 different genotypes have been isolated around the world, there is only one serotype. Measles is highly contagious. Infected person will often transmit the virus to over 90% of unprotected close contacts. Humans are natural hosts of the virus; animal reservoirs are not known to exist.

Measles Virus Based Vaccines for Cancer

Oncolytic viruses have shown great potential as cancer therapeutics. The ideal viral vector for cancer gene therapy eradicates a clinically significant fraction of malignant cells and leaves normal tissues unharmed. Recent advances in genetic engineering of measles virus allow insertion of therapeutic and diagnostic transgenes as well as complete retargeting of measles virus. These strategies resulted in the generation of recombinant measles viruses allowing non-invasive monitoring of viral replication and viral spread. The immune defense is a significant barrier for efficient viral gene therapy. Immune-evasive strategies have successfully been developed for measles virus enhancing its efficacy.

Attenuated Measles Viruses as Attractive Oncolytic Agents

Safety concerns arising from the use of oncolytic viruses for human cancer therapy can be divided into two areas: risk to the patient and risk to the population. To minimize risk to the patient, an ideal oncolytic virus should be selective for the tumor, nonpathogenic for normal host tissues, non-persistent and genetically stable. To minimize risk to the population, in addition to the above characteristics, the virus should be non-transmissible and preferably derived from a virus to which the population is generally immune. Attenuated measles viruses fulfill the above requirements. During the past fifty years, live attenuated measles viruses have been administered as vaccines to more than a billion people and the safety record has been outstanding.

Creative Biolabs is a leader in the field of vaccine development and has focused on the cancer vaccines for years. We have experienced experts and advanced platforms that are able to provide excellent services. If you are interested in our services, please contact us for more details.

Reference

1. Russell SJ. (2009). “Measles virus for cancer therapy.” Curr Top Microbiol Immunol 330, 213-241.

All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.